| abstract |
FIELD: pharmaceutics. n SUBSTANCE: invention relates to pharmaceutical industry, namely to composition for imaging and damaging of tumor cells, containing inorganic nanoparticles with size of 10–100 nm and dimensional dispersity of up to 6% of NaYF 4 , co-alloyed with ions of ytterbium (Yb) and erbium (Er) or ytterbium (Yb) and thulium (Tm), and including cytotoxic component represented by beta-isotope, which is isotope yttrium-90 ( 90 Y), nanoparticles are transferred into hydrophilic state by using coating of at least one of compounds selected from polymaleic anhydride of octadecene, polyethyleneimine, poly(D,L-lactide), poly(lactide-glycolide), silicon dioxide, tetramethylammonium hydroxide, wherein nanoparticles are linked with humanized mini-antibody scFv 4D5 or high affinity peptide of non-immunoglobulin nature DARPin-29, which are specific to cancer associated antigen HER-2/new. n EFFECT: invention provides possibility of local directed therapeutic effect due to damaging action of beta-radiation simultaneously with possibility of optical visualization of pathological center with lower risk of poisoning of nearby tissues. n 1 cl, 6 dwg |